A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the

Trial Details

NCT ID
NCT06004245
Phase
PHASE1
Sponsor
Vividion Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • VVD-133214
  • Pembrolizumab
  • Bevacizumab
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable …
  • Have received and then progressed following, or are intolerant to, standard therapy in the advanced setting
  • Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →